Literature DB >> 30272236

Lung Metastasis in Pediatric Thyroid Cancer: Radiological Pattern, Molecular Genetics, Response to Therapy, and Outcome.

Ali S Alzahrani1,2, Meshael Alswailem2, Yosra Moria1, Reem Almutairi1, Metib Alotaibi1, Avaniyapuram Kannan Murugan2, Ebtesam Qasem2, Balgees Alghamdi2, Hindi Al-Hindi3.   

Abstract

Context: Lung metastases are common in pediatric thyroid cancer (TC). We present an analysis of a series of lung metastases in pediatric TC. Patients and
Methods: Data from 20 patients (16 females, 4 males; median age, 14.5 years; range 10 to 18 years) were analyzed. The tumors included differentiated TC in 19 patients and poorly differentiated TC in 1 patient.
Results: Lung metastasis presented with three distinct radiological patterns: lung uptake on diagnostic radioactive iodine whole body scan (DxWBS) only in 3 patients (15%); lung uptake on DxWBS and CT scan as micrometastases (≤1 cm) in 16 patients (80%); and lung uptake on DxWBS and CT scan as macrometastases (>1 cm) in 1 patient (5%). Iodine-131 therapies were administered to all patients (median, three; range one to eight) with a median cumulative administered activity of 317.5 mCi (range, 109 to 682 mCi). None of the patients achieved a complete response but the biochemical response was substantial. During a median follow-up period of 8.2 years (range, 0.75 to 16.3 years), 1 patient (5%) died, 1 patient (5%) had a biochemically incomplete response, 2 patients (10%) had an indeterminate response, 1 patient (5%) had progressive structural disease, and 14 patients (70%) had stable structural disease. Mutational testing of 10 of 20 tumors revealed only two PIK3CA mutations in a single tumor. Conclusions: Lung metastases are common in pediatric TC and present most frequently with bilateral radioiodine-avid micrometastases. Known single point mutations in adult TC are rare in pediatric TC. The biochemical response to iodine-131 can be substantial but resolution of structural abnormalities is rare.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30272236     DOI: 10.1210/jc.2018-01690

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer.

Authors:  Aime T Franco; Julio C Ricarte-Filho; Theodore W Laetsch; Andrew J Bauer
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 19.456

2.  Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?

Authors:  Steven G Waguespack; Sanjit O Tewari; Naifa L Busaidy; Mark E Zafereo
Journal:  JCO Precis Oncol       Date:  2022-04

3.  Risk Factors for Pulmonary Metastasis in Differentiated Thyroid Carcinoma Patients and the Significance of Changes in Matrix Metalloproteinase 13 and microRNA-142 Levels.

Authors:  Xiaoyang Zhang; Zhenqi Lu; Guannan Zhang; Shuai Li; Aiguo Zhao; Yayun Miao; Wensheng Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-09-05       Impact factor: 3.009

4.  Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape.

Authors:  Marloes Nies; Rena Vassilopoulou-Sellin; Roland L Bassett; Sireesha Yedururi; Mark E Zafereo; Maria E Cabanillas; Steven I Sherman; Thera P Links; Steven G Waguespack
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

5.  Radioactive Iodine Therapy in Patients With Thyroid Carcinoma With Distant Metastases: A SEER-Based Study.

Authors:  Chenyuan Li; Qi Wu; Shengrong Sun
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.